Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population

Table 4

(a) Cost categories breakdown per patient per visit (PPPV) by demographic characteristics, IV drug, and number of drugs administered per visit: sensitivity analyses using alternative definition of mSTS diagnosis¹. (b) Cost categories breakdown per patient per visit (PPPV) by demographic characteristics, IV drug, and number of drugs administered per visit: sensitivity analyses excluding visits with administration costs in the top 1%¹.

(a)

Category	No. of patients	No. of visits	Total		IV drug		IV administration		Other visit-related services
			Average costs ($)	%	Average costs ($)	%	Average costs ($)	%	Average costs ($)	%
Total	1,023	11,777	2,293.60	100.0%	1,334.09	58.2%	392.81	17.1%	566.71	24.7%
Age
Less than 25	112	1,872	1,067.78	100.0%	435.96	40.8%	304.44	28.5%	327.38	30.7%
25 to 39	138	1,897	2,077.10	100.0%	1,153.72	55.5%	439.82	21.2%	483.56	23.3%
40 to 54	266	2,999	2,569.69	100.0%	1,486.01	57.8%	442.27	17.2%	641.41	25.0%
55 to 64	282	2,833	3,159.29	100.0%	1,941.58	61.5%	438.70	13.9%	779.01	24.7%
Greater than 64	225	2,176	2,029.35	100.0%	1,263.70	62.3%	299.93	14.8%	465.72	22.9%
Gender^2
Female	234	2,882	1,971.97	100.0%	1,135.12	57.6%	332.27	16.8%	504.58	25.6%
Male	234	3,156	1,856.48	100.0%	970.27	52.3%	347.30	18.7%	538.91	29.0%
Region
Midwest	189	2,235	2,206.58	100.0%	1,292.76	58.6%	423.45	19.2%	490.38	22.2%
Northeast	19	199	2,733.61	100.0%	1,665.07	60.9%	367.43	13.4%	701.11	25.6%
South	513	6,204	2,001.71	100.0%	1,021.93	51.1%	367.81	18.4%	611.97	30.6%
Southwest	95	985	1,620.03	100.0%	1,021.50	63.1%	308.51	19.0%	290.02	17.9%
West	207	2,154	3,491.98	100.0%	2,388.44	68.4%	473.90	13.6%	629.64	18.0%
Insurance type^3
Managed care	530	6,076	2,773.41	100.0%	1,646.46	59.4%	492.05	17.7%	634.91	22.9%
Medicare	217	2,200	1,756.68	100.0%	1,073.70	61.1%	271.13	15.4%	411.86	23.4%
Medicare HMO	19	181	1,808.04	100.0%	959.11	53.0%	274.88	15.2%	574.05	31.7%
Medicaid	61	756	814.99	100.0%	282.49	34.7%	93.08	11.4%	439.42	53.9%
Medicaid HMO	9	141	614.82	100.0%	233.36	38.0%	187.46	30.5%	193.99	31.6%
Indemnity	55	881	2,003.24	100.0%	1,200.97	60.0%	373.60	18.6%	428.67	21.4%
Other^4	132	1,542	2,270.35	100.0%	1,211.04	53.3%	365.92	16.1%	693.39	30.5%
IV drug (for mSTS)^5
Gemcitabine-based	374	2,926	3,438.08	100.0%	2,551.62	74.2%	366.02	10.6%	520.44	15.1%
Anthracycline-based	406	1,904	2,304.97	100.0%	1,006.55	43.7%	483.34	21.0%	815.08	35.4%
Alkylating-agents-based	383	3,416	1,494.70	100.0%	498.44	33.3%	430.76	28.8%	565.51	37.8%
Angiogenesis inhibitors	33	250	5,499.09	100.0%	4,413.94	80.3%	276.56	5.0%	808.59	14.7%
Taxane-based	141	945	2,280.97	100.0%	1,371.47	60.1%	416.92	18.3%	492.59	21.6%
Other	260	2,336	1,681.11	100.0%	953.29	56.7%	299.76	17.8%	428.06	25.5%
Number of administered IV drugs^6
One	831	6,874	1,717.75	100.0%	890.29	51.8%	295.14	17.2%	532.32	31.0%
Two	581	3,779	3,245.44	100.0%	2,178.48	67.1%	467.91	14.4%	599.05	18.5%
Three	148	963	2,449.85	100.0%	1,097.77	44.8%	696.15	28.4%	655.92	26.8%
Four	44	161	3,603.77	100.0%	1,876.43	52.1%	985.49	27.3%	741.85	20.6%

1: mSTS diagnosis defined as at least two medical claims with an ICD-9-CM diagnosis code of 171 and at least one medical claims with a diagnosis of a distant secondary malignant neoplasm (ICD-9-CM 196.XX-199.0). Treatment costs derived from the contracted allowed payment for a claim.
2: 644 patients were missing gender information.
3: Insurance type is defined at the time of the index mSTS diagnosis.
4: Other includes workers' compensation, Tricare, and self-pay.
5: Gemcitabine-based includes gemcitabine monotherapy and combination therapies. Anthracycline-based includes doxorubicin and epirubicin monotherapies and combination therapies. Alkylating-agents-based includes monotherapies and combination therapies with cisplatin, cyclophosphamide, dacarbazine, etoposide, ifosfamide, temozolomide, and topotecan. Angiogenesis inhibitors include bevacizumab monotherapy. Taxane-based includes docetaxel and paclitaxel monotherapies and combination therapies. Other includes actinomycin D, carboplatin, irinotecan, interferon, oxaliplatin, vincristine, and vinorelbine.
6: Number of mSTS treatments that were administered during the visit.

(b)

Category	No. of patients	No. of visits	Total		IV drug		IV administration		Other visit-related services
			Average costs ($)	%	Average costs ($)	%	Average costs ($)	%	Average costs ($)	%
Total	1,221	13,325	2,363.53	100.0%	1,417.87	60.0%	376.94	15.9%	568.72	24.1%
Age
Less than 25	116	1,934	1,104.42	100.0%	459.15	41.6%	307.88	27.9%	337.38	30.5%
25 to 39	151	1,953	2,170.22	100.0%	1,251.49	57.7%	423.35	19.5%	495.38	22.8%
40 to 54	313	3,377	2,565.44	100.0%	1,521.19	59.3%	402.53	15.7%	641.72	25.0%
55 to 64	344	3,274	3,227.77	100.0%	2,021.82	62.6%	429.45	13.3%	776.50	24.1%
Greater than 64	297	2,787	2,112.86	100.0%	1,365.08	64.6%	299.66	14.2%	448.12	21.2%
Gender^2
Female	289	3,352	2,143.16	100.0%	1,278.43	59.7%	337.16	15.7%	527.57	24.6%
Male	295	3,604	2,073.06	100.0%	1,158.90	55.9%	357.01	17.2%	557.15	26.9%
Region
Midwest	240	2,636	2,454.05	100.0%	1,478.01	60.2%	417.56	17.0%	558.48	22.8%
Northeast	41	339	2,242.53	100.0%	1,357.27	60.5%	383.64	17.1%	501.61	22.4%
South	604	6,969	2,084.97	100.0%	1,150.36	55.2%	347.76	16.7%	586.85	28.1%
Southwest	107	1,062	1,669.85	100.0%	1,023.82	61.3%	306.28	18.3%	339.75	20.3%
West	229	2,319	3,433.15	100.0%	2,342.75	68.2%	449.85	13.1%	640.56	18.7%
Insurance type^3
Managed care	615	6,647	2,838.48	100.0%	1,737.24	61.2%	468.51	16.5%	632.73	22.3%
Medicare	283	2,759	1,875.14	100.0%	1,180.06	62.9%	270.15	14.4%	424.93	22.7%
Medicare HMO	24	251	1,543.22	100.0%	880.70	57.1%	241.51	15.6%	421.01	27.3%
Medicaid	67	787	859.31	100.0%	344.74	40.1%	91.61	10.7%	422.96	49.2%
Medicaid HMO	10	145	709.35	100.0%	334.71	47.2%	185.94	26.2%	188.70	26.6%
Indemnity	68	1,036	2,199.25	100.0%	1,359.22	61.8%	371.24	16.9%	468.80	21.3%
Other^4	154	1,700	2,357.83	100.0%	1,259.37	53.4%	364.05	15.4%	734.42	31.1%
IV drug (for mSTS)^5
Gemcitabine-based	429	3,305	3,290.15	100.0%	2,439.82	74.2%	354.74	10.8%	495.59	15.1%
Anthracycline-based	423	1,925	2,275.39	100.0%	1,022.92	45.0%	432.97	19.0%	819.50	36.0%
Alkylating-agents-based	419	3,686	1,396.09	100.0%	441.77	31.6%	405.93	29.1%	548.39	39.3%
Angiogenesis inhibitors	58	367	5,217.74	100.0%	4,275.64	81.9%	281.20	5.4%	660.90	12.7%
Taxane-based	172	1,106	2,141.45	100.0%	1,300.21	60.7%	392.87	18.3%	448.37	20.9%
Other	348	2,936	2,319.72	100.0%	1,439.00	62.0%	334.77	14.4%	545.96	23.5%
Number of administered IV drugs^6
One	997	7,994	1,842.21	100.0%	998.14	54.2%	300.77	16.3%	543.30	29.5%
Two	670	4,229	3,333.67	100.0%	2,291.94	68.8%	456.61	13.7%	585.11	17.6%
Three	156	966	2,353.14	100.0%	1,023.01	43.5%	613.09	26.1%	717.04	30.5%
Four	39	136	2,913.93	100.0%	1,714.22	58.8%	699.57	24.0%	500.14	17.2%

1: Treatment costs derived from the contracted allowed payment for a claim.
2: 644 patients were missing gender information.
3: Insurance type is defined at the time of the index mSTS diagnosis.
4: Other includes workers' compensation, Tricare, and self-pay.
5: Gemcitabine-based includes gemcitabine monotherapy and combination therapies. Anthracycline-based includes doxorubicin and epirubicin monotherapies and combination therapies. Alkylating-agents-based includes monotherapies and combination therapies with cisplatin, cyclophosphamide, dacarbazine, etoposide, ifosfamide, temozolomide, and topotecan. Angiogenesis inhibitors include bevacizumab monotherapy. Taxane-based includes docetaxel and paclitaxel monotherapies and combination therapies. Other includes actinomycin D, carboplatin, irinotecan, interferon, oxaliplatin, vincristine, and vinorelbine.
6: Number of mSTS treatments that were administered during the visit.